ペフィシチニブによって寛解達成した関節リウマチ; 2つの日本人を対象としたフェーズ3治験の事後解析 (RAJ3 と RAJ4)
Mod Rheumatol 2023;34(3):453–65 doi: 10.1093/mr/road059
Pots hoc analysis of peficitinib Phase 3 trials shows that continued treatment with peficitinib up to Week 52 is linked to improved remission rates in Asian patients with RA.